473A Stock Overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.96 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.35 |
| Beta | 2.38 |
| 1 Month Change | -25.19% |
| 3 Month Change | 50.78% |
| 1 Year Change | -20.90% |
| 3 Year Change | -79.29% |
| 5 Year Change | -78.07% |
| Change since IPO | -93.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 473A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.4% | -0.2% | 0.5% |
| 1Y | -20.9% | -22.8% | 1.3% |
Return vs Industry: 473A exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: 473A underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 473A volatility | |
|---|---|
| 473A Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 473A's share price has been volatile over the past 3 months.
Volatility Over Time: 473A's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 449 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc Fundamentals Summary
| 473A fundamental statistics | |
|---|---|
| Market cap | €257.29m |
| Earnings (TTM) | -€106.15m |
| Revenue (TTM) | €56.19m |
4.5x
P/S Ratio-2.4x
P/E RatioIs 473A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 473A income statement (TTM) | |
|---|---|
| Revenue | US$60.28m |
| Cost of Revenue | US$126.51m |
| Gross Profit | -US$66.23m |
| Other Expenses | US$47.64m |
| Earnings | -US$113.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -109.87% |
| Net Profit Margin | -188.90% |
| Debt/Equity Ratio | 0% |
How did 473A perform over the long term?
See historical performance and comparison